These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27603962)

  • 1. Daclizumab (Zinbryta) for multiple sclerosis.
    Med Lett Drugs Ther; 2016 Sep; 58(1503):117-9. PubMed ID: 27603962
    [No Abstract]   [Full Text] [Related]  

  • 2. Daclizumab and its use in multiple sclerosis treatment.
    Milo R; Osherov M
    Drugs Today (Barc); 2017 Jan; 53(1):7-18. PubMed ID: 28387383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
    Osherov M; Milo R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies.
    Giovannoni G; Kappos L; Gold R; Khatri BO; Selmaj K; Umans K; Greenberg SJ; Sweetser M; Elkins J; McCroskery P
    Mult Scler Relat Disord; 2016 Sep; 9():36-46. PubMed ID: 27645341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of Latin American Neuroimmunologists on the Treatment of Multiple Sclerosis with Monoclonal Antibodies.
    Fragoso YD
    Curr Drug Saf; 2015; 10(3):217-20. PubMed ID: 25895725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L; Wiendl H; Selmaj K; Arnold DL; Havrdova E; Boyko A; Kaufman M; Rose J; Greenberg S; Sweetser M; Riester K; O'Neill G; Elkins J
    N Engl J Med; 2015 Oct; 373(15):1418-28. PubMed ID: 26444729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ▼ Daclizumab for MS.
    Drug Ther Bull; 2017 Feb; 55(2):18-21. PubMed ID: 28183723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclizumab in multiple sclerosis: a high-yield extension study.
    Barkhof F; Ciccarelli O
    Lancet Neurol; 2014 May; 13(5):443-4. PubMed ID: 24656610
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
    Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
    BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis.
    Reardon J; Perumal JS
    Drug Des Devel Ther; 2013; 7():1187-93. PubMed ID: 24143075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated.
    Immunotherapy; 2010 Jul; 2(4):437. PubMed ID: 20635996
    [No Abstract]   [Full Text] [Related]  

  • 12. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
    Giovannoni G; Gold R; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; McNeill M; Amaravadi L; Sweetser M; Elkins J; O'Neill G;
    Lancet Neurol; 2014 May; 13(5):472-81. PubMed ID: 24656609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R; Giovannoni G; Selmaj K; Havrdova E; Montalban X; Radue EW; Stefoski D; Robinson R; Riester K; Rana J; Elkins J; O'Neill G;
    Lancet; 2013 Jun; 381(9884):2167-75. PubMed ID: 23562009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
    Hradilek P; Zeman D; Tudik I; Zapletalova O; Ulmann V
    Mult Scler; 2014 Apr; 20(5):639-40. PubMed ID: 23959714
    [No Abstract]   [Full Text] [Related]  

  • 16. Daclizumab for the treatment of relapsing-remitting multiple sclerosis.
    Herwerth M; Hemmer B
    Expert Opin Biol Ther; 2017 Jun; 17(6):747-753. PubMed ID: 28286970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.
    Martin R
    Clin Immunol; 2012 Jan; 142(1):9-14. PubMed ID: 22284868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on anti-CD25: daclizumab in MS.
    Schippling DS; Martin R
    Int MS J; 2008 Sep; 15(3):94-8. PubMed ID: 18808743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.
    Sheridan JP; Robinson RR; Rose JW
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):9-19. PubMed ID: 24308792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.